Development and scale-up of an optimized route to the ALK inhibitor CEP-28122

…, RC Roemmele, JJ Haley Jr, DR Mowrey…

文献索引：Allwein, Shawn P.; Roemmele, Renee C.; Haley, James J.; Mowrey, Dale R.; Petrillo, Daniel E.; Reif, James J.; Gingrich, Diane E.; Bakale, Roger P. Organic Process Research and Development, 2012 , vol. 16, # 1 p. 148 - 155

全文：HTML全文

被引用次数: 18

摘要

Evolution of the process strategies to prepare CEP-28122, an anaplastic lymphoma kinase (ALK) inhibitor, is presented. The initial medicinal chemistry route, used for the preparation of key supplies for biological screening, is reviewed. In addition, the process research and development of the final optimized process for manufacture of preclinical and clinical supplies is discussed. Details regarding a blocking group strategy for selective nitration; ...